Evolus (NASDAQ:EOLS) Earns Buy Rating from BTIG Research

Key Points

• BTIG Research has reaffirmed a "buy" rating for Evolus, setting a price target of $18.00, indicating a potential upside of 134.53% from its current price.
• The stock has received mixed ratings from analysts, with one downgrade to a "sell" rating and a majority maintaining a "buy" or "hold" rating, resulting in an average target price of $21.25.
• Evolus saw notable insider transactions, including a director purchasing 30,000 shares and a CMO selling 5,722 shares, reflecting ongoing interest and activity among company leadership.

Evolus (NASDAQ:EOLS - Get Free Report)'s stock had its "buy" rating restated by research analysts at BTIG Research in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $18.00 price objective on the stock. BTIG Research's price objective points to a potential upside of 150.35% from the company's current price.

A number of other research firms have also weighed in on EOLS. Wall Street Zen lowered shares of Evolus from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. HC Wainwright lowered their price target on shares of Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. Finally, Needham & Company LLC reaffirmed a "hold" rating and set a $22.00 price target on shares of Evolus in a report on Wednesday, August 6th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Evolus presently has a consensus rating of "Moderate Buy" and an average target price of $21.25.

Evolus Trading Down 4.3%

Shares of Evolus stock traded down $0.32 during trading hours on Monday, hitting $7.19. The company's stock had a trading volume of 707,868 shares, compared to its average volume of 864,454. Evolus has a 1-year low of $5.71 and a 1-year high of $17.82. The business has a fifty day moving average of $8.08 and a 200 day moving average of $9.96. The company has a market capitalization of $465.05 million, a PE ratio of -7.34 and a beta of 1.07. The company has a quick ratio of 1.86, a current ratio of 2.27 and a debt-to-equity ratio of 22.00.

Insider Buying and Selling at Evolus

In related news, Director Brady Stewart acquired 30,000 shares of Evolus stock in a transaction on Friday, August 15th. The shares were purchased at an average cost of $6.82 per share, for a total transaction of $204,600.00. Following the purchase, the director directly owned 88,629 shares of the company's stock, valued at $604,449.78. The trade was a 51.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Moatazedi sold 16,582 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.89, for a total transaction of $163,995.98. Following the transaction, the insider owned 364,927 shares in the company, valued at $3,609,128.03. This trade represents a 4.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Manchester Capital Management LLC bought a new position in shares of Evolus in the 2nd quarter worth about $26,000. AlphaQuest LLC bought a new position in shares of Evolus in the 1st quarter worth about $39,000. State of Wyoming lifted its position in shares of Evolus by 988.1% in the 1st quarter. State of Wyoming now owns 3,754 shares of the company's stock worth $45,000 after buying an additional 3,409 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Evolus by 340.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company's stock worth $68,000 after buying an additional 5,691 shares during the last quarter. Finally, IFP Advisors Inc lifted its position in shares of Evolus by 99.0% in the 1st quarter. IFP Advisors Inc now owns 9,427 shares of the company's stock worth $113,000 after buying an additional 4,691 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.